TIVc

BIOLOGICAL2 trials

Sponsors

Novartis Vaccines

Conditions

Human InfluenzaInfluenza

Phase 3

Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above

CompletedNCT01880697

Novartis VaccinesHuman Influenza

Start: 2013-08-31End: 2013-09-30Updated: 2017-02-23

A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

CompletedNCT01998477

Novartis VaccinesInfluenza

Start: 2013-10-31End: 2014-07-31Updated: 2017-04-21

Related Papers

Safety and tolerability of cell culture-derived and egg-derived trivalent influenza vaccines in 3 to <18-year-old children and adolescents at risk of influenza-related complications.

2016-06-234 citations